FINWIRES · TerminalLIVE
FINWIRES

US Equity Futures Decline Pre-Bell as Trump Orders US Blockade of Strait of Hormuz After Talks With Iran Fail

-- US equity futures were lower pre-bell on Monday after President Donald Trump ordered a blockade of the Strait of Hormuz following the failure of US and Iran to reach an agreement in peace talks in Islamabad.

Dow Jones Industrial Average futures were 1% lower, S&P 500 futures were down 0.6%, and Nasdaq futures were 0.6% lower.

"Effective immediately, the United States Navy, the Finest in the World, will begin the process of BLOCKADING any and all Ships trying to enter, or leave, the Strait of Hormuz," Trump said in a post on Truth Social on Sunday.

Trump said that an agreement was not reached due to Iran's unwillingness to give up its nuclear ambitions, while Iran said the US had made unreasonable demands.

Oil prices were higher, with front-month global benchmark North Sea Brent crude up 7.4% at $102.26 per barrel and US West Texas Intermediate crude 7.8% higher at $104.11 per barrel.

Existing Home Sales, scheduled for release at 10 am ET, are seen declining 0.8% for March after an increase of 1.7% in the prior month, according to estimates compiled by Bloomberg.

In other world markets, Japan's Nikkei closed 0.7% lower, Hong Kong's Hang Seng ended 0.9% lower, and China's Shanghai Composite finished 0.1% higher. Meanwhile, the UK's FTSE 100 was down 0.4%, and Germany's DAX index was lower by 1.2% in Europe's early afternoon session.

In equities, a number of energy firms saw stock gains as oil prices once again breached the $100 mark. Exxon Mobil (XOM) shares gained 1.6%, ConocoPhillips (COP) shares increased 2%, and Equinor (EQNR) stock rose 2.2%.

On the losing side, Best Buy (BBY) stock fell 4.5% after the company's stock was downgraded by Goldman Sachs to sell from buy.

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524